Celgene closed at $73.42 in the latest trading session, marking a +1.66% move from the prior day. The stock outpaced the S&P 500's daily gain of 1.09%. At the same time, the Dow added 1.13%, and the tech-heavy Nasdaq gained 1.51%.
Coming into today, shares of the biotechnology company had lost 4.48% in the past month. In that same time, the Medical sector gained 4.8%, while the S&P 500 gained 1.92%.
Wall Street will be looking for positivity from CELG as it approaches its next earnings report date. This is expected to be January 24, 2019. In that report, analysts expect CELG to post earnings of $2.31 per share. This would mark year-over-year growth of 15.5%. Meanwhile, our latest consensus estimate is calling for revenue of $3.97 billion, up 14% from the prior-year quarter.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $8.80 per share and revenue of $15.20 billion. These totals would mark changes of +18.28% and +16.93%, respectively, from last year.
Any recent changes to analyst estimates for CELG should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. CELG is holding a Zacks Rank of #3 (Hold) right now.
Investors should also note CELG's current valuation metrics, including its Forward P/E ratio of 8.21. For comparison, its industry has an average Forward P/E of 24.65, which means CELG is trading at a discount to the group.
We can also see that CELG currently has a PEG ratio of 0.38. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. Medical - Biomedical and Genetics stocks are, on average, holding a PEG ratio of 1.62 based on yesterday's closing prices.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 73, putting it in the top 28% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.
Image: Bigstock
Celgene (CELG) Outpaces Stock Market Gains: What You Should Know
Celgene closed at $73.42 in the latest trading session, marking a +1.66% move from the prior day. The stock outpaced the S&P 500's daily gain of 1.09%. At the same time, the Dow added 1.13%, and the tech-heavy Nasdaq gained 1.51%.
Coming into today, shares of the biotechnology company had lost 4.48% in the past month. In that same time, the Medical sector gained 4.8%, while the S&P 500 gained 1.92%.
Wall Street will be looking for positivity from CELG as it approaches its next earnings report date. This is expected to be January 24, 2019. In that report, analysts expect CELG to post earnings of $2.31 per share. This would mark year-over-year growth of 15.5%. Meanwhile, our latest consensus estimate is calling for revenue of $3.97 billion, up 14% from the prior-year quarter.
Looking at the full year, our Zacks Consensus Estimates suggest analysts are expecting earnings of $8.80 per share and revenue of $15.20 billion. These totals would mark changes of +18.28% and +16.93%, respectively, from last year.
Any recent changes to analyst estimates for CELG should also be noted by investors. These revisions typically reflect the latest short-term business trends, which can change frequently. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. We developed the Zacks Rank to capitalize on this phenomenon. Our system takes these estimate changes into account and delivers a clear, actionable rating model.
Ranging from #1 (Strong Buy) to #5 (Strong Sell), the Zacks Rank system has a proven, outside-audited track record of outperformance, with #1 stocks returning an average of +25% annually since 1988. Over the past month, the Zacks Consensus EPS estimate remained stagnant. CELG is holding a Zacks Rank of #3 (Hold) right now.
Investors should also note CELG's current valuation metrics, including its Forward P/E ratio of 8.21. For comparison, its industry has an average Forward P/E of 24.65, which means CELG is trading at a discount to the group.
We can also see that CELG currently has a PEG ratio of 0.38. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. Medical - Biomedical and Genetics stocks are, on average, holding a PEG ratio of 1.62 based on yesterday's closing prices.
The Medical - Biomedical and Genetics industry is part of the Medical sector. This group has a Zacks Industry Rank of 73, putting it in the top 28% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.